ERBB2 (P780_Y781insGSP)

ERBB2 · Variant type: indel · HGVS: p.P780_Y781insGSP

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Entrectinib	100.0%	0.0%	93.69
2	Lorlatinib	100.0%	0.0%	97.24
3	Gilteritinib	99.8%	0.2%	88.97
4	Ceritinib	99.8%	0.2%	95.44
5	Alectinib	99.5%	0.5%	95.49
6	Brigatinib	99.5%	0.5%	82.96
7	Repotrectinib	99.3%	0.7%	84.21
8	Crizotinib	98.0%	2.0%	91.39
9	Sunitinib	85.9%	14.1%	91.73
10	Nintedanib	72.8%	27.2%	90.23
11	Bosutinib	70.5%	29.5%	87.22
12	Osimertinib	70.1%	29.9%	97.24
13	Pralsetinib	69.2%	30.8%	93.43
14	Alpelisib	64.7%	35.3%	97.22
15	Fostamatinib	47.8%	52.2%	96.74
16	Ruxolitinib	38.2%	61.8%	98.25
17	Pacritinib	28.8%	71.2%	88.64
18	Lazertinib	27.8%	72.2%	97.47
19	Baricitinib	24.0%	76.0%	97.99
20	Tenalisib	18.4%	81.6%	97.98
21	Defactinib	17.4%	82.6%	92.68
22	Neratinib	13.8%	86.2%	93.18
23	Vandetanib	13.7%	86.3%	95.74
24	Tepotinib	10.1%	89.9%	99.75
25	Axitinib	9.9%	90.1%	93.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Entrectinib	100.0%	—	—
Lorlatinib	100.0%	—	—
Gilteritinib	99.8%	—	—
Ceritinib	99.8%	—	—
Alectinib	99.5%	—	—
Brigatinib	99.5%	—	—
Repotrectinib	99.3%	—	—
Crizotinib	98.0%	—	—
Sunitinib	85.9%	—	—
Nintedanib	72.8%	—	—
Bosutinib	70.5%	—	—
Osimertinib	70.1%	—	—
Pralsetinib	69.2%	—	—
Alpelisib	64.7%	—	—
Fostamatinib	47.8%	—	—
Ruxolitinib	38.2%	—	—
Pacritinib	28.8%	—	—
Lazertinib	27.8%	—	—
Baricitinib	24.0%	—	—
Tenalisib	18.4%	—	—
Defactinib	17.4%	—	—
Neratinib	13.8%	—	—
Vandetanib	13.7%	—	—
Tepotinib	10.1%	—	—
Axitinib	9.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 20.9ms